Inhibrx Biosciences (INBX) Net Cash Flow (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Net Cash Flow data on file, last reported at -$28.9 million in Q4 2025.

• On a quarterly basis, Net Cash Flow rose 33.99% year-over-year to -$28.9 million in Q4 2025; TTM through Dec 2025 was -$28.4 million, a 77.36% increase from a year earlier, with the FY2025 full-year figure at -$28.4 million, up 77.36% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$28.9 million, up from -$33.5 million in the prior quarter.
• Over the last five years, Net Cash Flow for INBX reached as high as $144.8 million in Q3 2023 and fell as low as -$59.4 million in Q4 2023.
• Historically, Net Cash Flow has averaged -$6.8 million across 3 years, with a median of -$29.4 million in 2025.
• Across the five-year window, Net Cash Flow slumped 121.08% in 2024 and jumped 351.26% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$59.4 million in 2023, then rose by 26.37% to -$43.7 million in 2024, then surged by 33.99% to -$28.9 million in 2025.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$28.9 million in Q4 2025, -$33.5 million in Q3 2025, and -$30.0 million in Q2 2025.